April Journal-2009.p65 - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 3 (2) 128-137, April 2009. ISSN 0973-8916
10. Guan, K.L., Jenkins, C.W., Li, Y., Nichols,
M.A., Wu, X., O’Keefe, C.L., Matera, A.G.
and Xiong, Y. (1994). Growth suppression
by p18, a p16INK4/MTSer1- and
p14INK4B/MTS2-related CDK6 inhibitor,
correlates with wild-type pRb function.
Genes Dev., 8: 2939–2952.
11. James, M.C. and Peters, G. (2000).
Alternative product of the p16/CKDN2A
locus connects the Rb and p53 tumor
suppressors. Prog. Cell Cycle Res., 4: 71–81.
12. Hannon, G.J. and Beach, D. (1994). p15
INK 4B is a potential effector of TGF-betainduced
cell cycle arrest. Nature, 371: 257–
261.
13. Latres, E., Malumbres, M., Sotillo, R.,
Martin, J., Ortega, S., Martin-Caballero, J.,
Flores, J.M., Cordon-Cardo, C. and
Barbacid, M. (2000). Limited overlapping
roles of P15 (INK4b) and P18 (INK4c) cell
cycle inhibitors in proliferation and
tumorigenesis. EMBO J., 19: 3496–3506.
14. Franklin, D.S., Godfrey, V.L., Lee, H.,
Kovalev, G.I., Schoonhoven, R., Chen-
Kiang, S., Su, L. and Xiong, Y. (1998). CDK
inhibitors p18 (INK4c) and p27 (KIP1)
mediate two separate pathways to
collaboratively suppress pituitary
tumorigenesis. Genes Dev., 12: 2899–2911.
15. Hirai, H., Roussel, M.F., Kato, J.Y.,
Ashmun, R.A. and Sherr, C.J. (1995). Novel
INK4 proteins, p19 and p18, are specific
inhibitors of the cyclin D-dependent kinases
CDK4 and CDK6. Mol. Cell Biol., 15: 2672–
2681.
16. Tavera-Mendoza, L.E, Wang, T.T., White,
J.H. (2006) p19INK4D and cell death. Cell
Cycle, 5: 596–598.
17. Yan, Y., Frisen, J., Lee, M.H., Massague, J.
and Barbacid, M. (1997). Ablation of the
136
CDK inhibitor p57KIP2 results in increased
apoptosis and delayed differentiation during
mouse development. Genes Dev., 11: 973–983.
18. Heinen, A., Kremer, D., Gottle, P., Kruse,
F., Hasse, B., Lehmann, H., Hartung, H.P.,
and Kury, P. (2008). The cyclin-dependent
kinase inhibitor p57kip2 is a negative
regulator of Schwann cell differentiation and
in vitro myelination. PNAS, 105: 8748–8753.
19. Sherr, C.J. and Roberts, J.M. (1999). CDK
inhibitors: Positive and negative regulators
of G 1
-phase progression. Genes & Dev., 13:
1501–1512.
20. Murray, A.W. (2004). Recycling the cell
cycle: Cyclins revisited. Cell, 116: 221–234.
21. Polyak, K., Kato, J.Y., Solomon, M.J., Sherr,
C.J., Massague, J., Roberts, J.M., and Koff,
A. (1994). p27KIP1, a cyclin–Cdk inhibitor,
links transforming growth factor-â and
contact inhibition to cell cycle arrest. Genes
& Dev., 8: 9–22.
22. Lee, M.H., Reynisdottir, I., and Massague,
J. (1995). Cloning of p57KIP2, a cyclindependent
kinase inhibitor with unique
domain structure and tissue distribution.
Genes & Dev., 9: 639–649.
23. Ishida, N., Kitagawa, M., Hatakeyama, S.,
and Nakayama, K. (2000). Phosphorylation
at serine 10, a major phosphorylation site of
p27 (KIP1). increases its protein stability.
J. Biol. Chem., 275: 25146–25154.
24. Nakayama, K., Ishida, N., Shirane, M.,
Inomata, A., Inoue, T., Shishido, N., Horii,
I., and Loh, D.Y. (1996). Mice lacking p27
(KIP1) display increased body size, multiple
organ hyperplasia, retinal dysplasia, and
pituitary tumors. Cell, 85: 707–720.
25. Toyoshima, H. and Hunter, T. (1994). p27,
a novel inhibitor of G 1
cyclin–Cdk protein
kinase activity, is related to p21. Cell, 78:
67–74.
Regulation of CDK inhibitors